Selective and augmented β-glucuronidase expression combined with DOX-GA3 application elicits the potent suppression of prostate cancer

Wang,Longxin; Dong,Jie; Wei,Ming; Wen,Weihong; Gao,Jianping; Zhang,Zhengyu; Qin,Weijun

doi:10.3892/or.2015.4454

Selective and augmented β-glucuronidase expression combined with DOX-GA3 application elicits the potent suppression of prostate cancer

Authors:
- Longxin Wang
- Jie Dong
- Ming Wei
- Weihong Wen
- Jianping Gao
- Zhengyu Zhang
- Weijun Qin
View Affiliations

Affiliations: Department of Urology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210002, P.R. China, Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, State Key Laboratory of Cancer Biology, Department of Immunology, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
Published online on: November 26, 2015 https://doi.org/10.3892/or.2015.4454
Pages: 1417-1424

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was carried out to evaluate the specific and amplified β-glucuronidase (βG) expression in prostate cancer cells by using a prostate‑specific antigen (PSA) promoter-controlled bicistronic adenovirus and to evaluate the specific killing of prostate cancer cells after the application of the prodrug DOX‑GA3. Bicistronic adenoviral expression vectors were constructed, and the effectiveness of specific and amplified expression was evaluated using luciferase and EGFP as reporter genes. βG expression was detected in LNCaP cells after they were infected with the βG‑expressing PSA promoter-controlled bicistronic adenovirus. MTT assays were conducted to evaluate the cytoxicity on the infected cells after the application of the prodrug DOX‑GA3. Tumor growth inhibition was also evaluated in nude mice after treatment with the βG‑expressing adenovirus and DOX‑GA3. Selective and amplified expression was observed in the PSA-producing LNCaP cells, but not in the PSA‑non‑producing DU145 cells. Potent cytotoxity and a strong bystander effect were observed in the LNCaP cells after infection with the βG‑expressing adenovirus and the application of DOX‑GA3. Intravenous injection of a GAL4 regulated bicistronic adenovirus vector constructed to express βG under the control of the PSA promoter (Ad/PSAP‑GV16‑βG) and the application of DOX‑GA3 strongly inhibited tumor growth and prolonged the survival time of tumor‑bearing nude mice. Selective and amplified βG expression together with the prodrug DOX‑GA3 had an increased antitumor effect, showing great potential for prostate cancer therapy.

View Figures

View References

1	MacRae EJ, Giannoudis A, Ryan R, Brown NJ, Hamdy FC, Maitland N and Lewis CE: Gene therapy for prostate cancer: Current strategies and new cell-based approaches. Prostate. 66:470–494. 2006. View Article : Google Scholar
2	Trojan L, Kiknavelidze K, Knoll T, Alken P and Michel MS: Prostate cancer therapy: Standard management, new options and experimental approaches. Anticancer Res. 25:551–561. 2005.PubMed/NCBI
3	Ward JF and Moul JW: Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol. 15:181–186. 2005. View Article : Google Scholar : PubMed/NCBI
4	Ward JF and Moul JW: Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol. 15:187–195. 2005. View Article : Google Scholar : PubMed/NCBI
5	de Graaf M, Boven E, Scheeren HW, Haisma HJ and Pinedo HM: Beta-glucuronidase-mediated drug release. Curr Pharm Des. 8:1391–1403. 2002. View Article : Google Scholar : PubMed/NCBI
6	Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW, Pinedo HM and Haisma HJ: Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate. Int J Cancer. 91:550–554. 2001. View Article : Google Scholar : PubMed/NCBI
7	Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW, Pinedo HM and Haisma HJ: A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: Distribution and efficacy in experimental human ovarian cancer. Br J Cancer. 84:550–557. 2001. View Article : Google Scholar : PubMed/NCBI
8	van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF and Hospers GA: Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther. 2:307–322. 2002. View Article : Google Scholar : PubMed/NCBI
9	Mesnil M and Yamasaki H: Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication. Cancer Res. 60:3989–3999. 2000.PubMed/NCBI
10	Fonseca MJ, Storm G, Hennink WE, Gerritsen WR and Haisma J: Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy. J Gene Med. 1:407–414. 1999. View Article : Google Scholar
11	de Graaf M, Boven E, Oosterhoff D, van der Meulen-Muileman IH, Huls GA, Gerritsen WR, Haisma HJ and Pinedo HM: A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br J Cancer. 86:811–818. 2002. View Article : Google Scholar : PubMed/NCBI
12	Wei G, Loktionova NA, Pegg AE and Moschel RC: Beta-glucuronidase-cleavable prodrugs of O⁶-benzylguanine and O⁶-benzyl-2′-deoxyguanosine. J Med Chem. 48:256–261. 2005. View Article : Google Scholar : PubMed/NCBI
13	Houba PH, Boven E, Erkelens CA, Leenders RG, Scheeren JW, Pinedo HM and Haisma HJ: The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts. Br J Cancer. 78:1600–1606. 1998. View Article : Google Scholar : PubMed/NCBI
14	Sperker B, Werner U, Mürdter TE, Tekkaya C, Fritz P, Wacke R, Adam U, Gerken M, Drewelow B and Kroemer HK: Expression and function of beta-glucuronidase in pancreatic cancer: Potential role in drug targeting. Naunyn Schmiedebergs Arch Pharmacol. 362:110–115. 2000. View Article : Google Scholar : PubMed/NCBI
15	Park HS, Cheon J, Cho HY, Ko YH, Bae JH, Moon DG and Kim JJ: In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia. Gene Ther. 10:1129–1134. 2003. View Article : Google Scholar : PubMed/NCBI
16	Yu D, Chen D, Chiu C, Razmazma B, Chow YH and Pang S: Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther. 8:628–635. 2001. View Article : Google Scholar : PubMed/NCBI
17	Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA and Fang B: Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res. 62:3620–3625. 2002.PubMed/NCBI
18	Nasu Y, Kusaka N, Saika T, Tsushima T and Kumon H: Suicide gene therapy for urogenital cancer: Current outcome and prospects. Mol Urol. 4:67–71. 2000. View Article : Google Scholar
19	Yazawa K, Fisher WE and Brunicardi FC: Current progress in suicide gene therapy for cancer. World J Surg. 26:783–789. 2002. View Article : Google Scholar : PubMed/NCBI
20	Poulsen TT, Pedersen N and Poulsen HS: Replacement and suicide gene therapy for targeted treatment of lung cancer. Clin Lung Cancer. 6:227–236. 2005. View Article : Google Scholar : PubMed/NCBI
21	Nicholas TW, Read SB, Burrows FJ and Kruse CA: Suicide gene therapy with herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol histopathol. 18:495–507. 2003.PubMed/NCBI
22	Fillat C, Carrió M, Cascante A and Sangro B: Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: Fifteen years of application. Curr Gene Ther. 3:13–26. 2003. View Article : Google Scholar : PubMed/NCBI
23	Satoh T, Irie A, Egawa S and Baba S: In situ gene therapy for prostate cancer. Curr Gene Ther. 5:111–119. 2005. View Article : Google Scholar : PubMed/NCBI
24	Shalev M, Kadmon D, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC, Herman JR, Adler HL, Scardino PT and Miles BJ: Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol. 163:1747–1750. 2000. View Article : Google Scholar : PubMed/NCBI
25	Biela BH, Khawli LA, Hu P and Epstein AL: Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Cancer Biother Radiopharm. 18:339–353. 2003. View Article : Google Scholar : PubMed/NCBI
26	Haisma HJ, Sernee MF, Hooijberg E, Brakenhoff RH, vd Meulen-Muileman IH, Pinedo HM and Boven E: Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Blood. 92:184–190. 1998.PubMed/NCBI
27	Kaliberov SA, Chiz S, Kaliberova LN, Krendelchtchikova V, Della Manna D, Zhou T and Buchsbaum DJ: Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity. Cancer Gene Ther. 13:203–214. 2006. View Article : Google Scholar
28	Djeha HA, Todryk SM, Pelech S, Wrighton CJ, Irvine AS, Mountain A and Lipinski KS: Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70. Cancer Gene Ther. 12:560–571. 2005. View Article : Google Scholar : PubMed/NCBI
29	Miki K, Xu M, Gupta A, Ba Y, Tan Y, Al-Refaie W, Bouvet M, Makuuchi M, Moossa AR and Hoffman RM: Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res. 61:6805–6810. 2001.PubMed/NCBI
30	Denny WA: Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J Biomed Biotechnol. 2003:48–70. 2003. View Article : Google Scholar : PubMed/NCBI
31	Dabrowska A, Szary J, Kowalczuk M, Szala S and Ugorski M: CEA-negative glioblastoma and melanoma cells are sensitive to cytosine deaminase/5-fluorocytosine therapy directed by the carcinoembryonic antigen promoter. Acta Biochim Pol. 51:723–732. 2004.PubMed/NCBI
32	Ikegami S, Tadakuma T, Suzuki S, Yoshimura I, Asano T and Hayakawa M: Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jpn J Cancer Res. 93:1154–1163. 2002. View Article : Google Scholar : PubMed/NCBI
33	Peng W, Chen J, Huang YH and Sawicki JA: Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells. Gene Ther. 12:1573–1580. 2005. View Article : Google Scholar : PubMed/NCBI
34	Qiao J, Doubrovin M, Sauter BV, Huang Y, Guo ZS, Balatoni J, Akhurst T, Blasberg RG, Tjuvajev JG, Chen SH, et al: Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther. 9:168–175. 2002. View Article : Google Scholar : PubMed/NCBI
35	Ueda K, Iwahashi M, Nakamori M, Nakamura M, Matsuura I, Yamaue H and Tanimura H: Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res. 61:6158–6162. 2001.PubMed/NCBI
36	Koch PE, Guo ZS, Kagawa S, Gu J, Roth JA and Fang B: Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol Ther. 3:278–283. 2001. View Article : Google Scholar : PubMed/NCBI
37	Ray S, Paulmurugan R, Hildebrandt I, Iyer M, Wu L, Carey M and Gambhir SS: Novel bidirectional vector strategy for amplification of therapeutic and reporter gene expression. Hum Gene Ther. 15:681–690. 2004. View Article : Google Scholar : PubMed/NCBI
38	Iyer M, Salazar FB, Lewis X, Zhang L, Wu L, Carey M and Gambhir SS: Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transgenic Res. 14:47–55. 2005. View Article : Google Scholar : PubMed/NCBI